Shares of Galena Biopharma, Inc. (NASDAQ:GALE) shot up 14.3% during trading on Thursday . The stock traded as high as $0.32 and last traded at $0.32. 1,552,260 shares were traded during trading, an increase of 45% from the average session volume of 1,069,747 shares. The stock had previously closed at $0.28.
A number of institutional investors and hedge funds have recently bought and sold shares of GALE. Renaissance Technologies LLC purchased a new stake in Galena Biopharma during the 1st quarter valued at approximately $976,000. Vaughan David Investments Inc. IL raised its stake in Galena Biopharma by 6,545.7% during the 3rd quarter. Vaughan David Investments Inc. IL now owns 864,076 shares of the biotechnology company’s stock valued at $20,893,000 after acquiring an additional 851,074 shares during the last quarter. Virtu KCG Holdings LLC raised its stake in Galena Biopharma by 677.4% during the 2nd quarter. Virtu KCG Holdings LLC now owns 224,050 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 195,230 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Galena Biopharma by 1.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,332,434 shares of the biotechnology company’s stock valued at $774,000 after acquiring an additional 13,302 shares during the last quarter. 19.00% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Galena Biopharma (GALE) Shares Up 14.3%” was published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3095036/galena-biopharma-gale-shares-up-14-3.html.
Galena Biopharma Company Profile
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Receive News & Ratings for Galena Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.